Celyad Oncology SA
CLYYF
$0.65
-$0.03-4.41%
OTC PK
| 12/31/2024 | 09/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -2.96% | 1,160.00% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -2.96% | 1,160.00% | |||
| Cost of Revenue | 0.00% | -66.67% | |||
| Gross Profit | -3.01% | 3,340.74% | |||
| SG&A Expenses | -3.04% | -14.09% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | 3.03% | -12.55% | |||
| Total Operating Expenses | -3.04% | -2.47% | |||
| Operating Income | 3.04% | 7.73% | |||
| Income Before Tax | 3.04% | 6.72% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 3.04% | 6.72% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 3.04% | 6.72% | |||
| EBIT | 3.04% | 7.73% | |||
| EBITDA | 1.36% | 5.25% | |||
| EPS Basic | 2.98% | 6.58% | |||
| Normalized Basic EPS | 3.45% | 6.07% | |||
| EPS Diluted | 2.98% | 6.58% | |||
| Normalized Diluted EPS | 3.45% | 6.07% | |||
| Average Basic Shares Outstanding | 0.00% | 0.00% | |||
| Average Diluted Shares Outstanding | 0.00% | 0.00% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||